Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 2/2000

01-04-2000 | Review

Transforming growth factor-β and breast cancer: Transforming growth factor-β/SMAD signaling defects and cancer

Author: Marcus Kretzschmar

Published in: Breast Cancer Research | Issue 2/2000

Login to get access

Abstract

Transforming growth factor-β (TGF-β) is a tumor suppressor, the function of which is compromised in many types of human cancer, including breast cancer. The tumor suppressive effects of TGF-β are caused by potent inhibition of cell proliferation due to cell cycle arrest in the G1 phase. Such antiproliferative responses are mediated by a signaling system that includes two types of cell surface receptors and intracellular signal transducers, the SMAD proteins. Different molecular mechanisms can lead to loss of antiproliferative TGF-β responses in tumor cells, including mutations in components of the signaling system and inhibition of the SMAD signaling pathway by aberrant activities of various regulatory molecules. Some of these mechanisms will be discussed, with emphasis on their potential involvement in breast tumorigenesis.
Literature
1.
Massagué J: TGFβ signal transduction. Annu Rev Biochem. 1998, 67: 753-791. 10.1146/annurev.biochem.67.1.753.PubMedCrossRef
2.
Arteaga CL, Dugger TC, Hurd SD: The multifunctional role of transforming growth factor (TGF)-βs on mammary epithelial cell biology. Breast Cancer Res Treat. 1996, 38: 49-56.PubMedCrossRef
3.
Reiss M, Barcellos-Hoff MH: Transforming growth factor-β in breast cancer: a working hypothesis. Breast Cancer Res Treat. 1997, 45: 81-95. 10.1023/A:1005865812918.PubMedCrossRef
4.
Pierce DFJ, Gorska AE, Chytil A, et al: Mammary tumor suppression by transforming growth factor beta 1 transgene expression. Proc Natl Acad Sci USA. 1995, 92: 4254-4258.PubMedPubMedCentralCrossRef
5.
Oft M, Peli J, Rudaz C, Schwarz H, Beug H, Reichmann E: TGF-β1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells. Genes Dev. 1996, 10: 2462-2477.PubMedCrossRef
6.
Welch DR, Fabra A, Nakajima M: Transforming growth factor β stimulates mammary adenocarcinoma cell invasion and metastatic potential. Proc Natl Acad Sci USA. 1990, 87: 7678-7682.PubMedPubMedCentralCrossRef
7.
Yin JJ, Selander K, Chirgwin JM, et al: TGF-β signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest. 1999, 103: 197-206.PubMedPubMedCentralCrossRef
8.
Oft M, Heider KH, Beug H: TGFβ signaling is necessary for carcinoma cell invasiveness and metastasis. Curr Biol. 1998, 8: 1243-1252. 10.1016/S0960-9822(07)00533-7.PubMedCrossRef
9.
Fynan TM, Reiss M: Resistance to inhibition of cell growth by transforming growth factor-β and its role in oncogenesis. Crit Rev Oncog. 1993, 4: 493-540.PubMed
10.
Alexandrow MG, Moses HL: Transforming growth factor β and cell cycle regulation. Cancer Res. 1995, 55: 1452-1457.PubMed
11.
Kretzschmar M, Massagué J: SMADs: mediators and regulators of TGFβ family signalling. Curr Opin Genet Dev. 1998, 8: 103-111. 10.1016/S0959-437X(98)80069-5.PubMedCrossRef
12.
Derynck R, Zhang Y, Feng XH: Smads: transcriptional activators of TGF-β responses. Cell. 1998, 95: 737-740.PubMedCrossRef
13.
Markowitz S, Wang J, Myeroff L, et al: Inactivation of the type II TGF-β receptor in colon cancer cells with microsatellite instability. Science. 1995, 268: 1336-1338. This study identifies mutations clustered within small repeated sequences in the type II TGF-β receptor gene in colon cancers with DNA repair defects, thereby linking DNA repair defects with the escape from TGF-β-mediated cell growth control in this type of cancer.PubMedCrossRef
14.
Myeroff LL, Parsons R, Kim S-J, et al: A transforming growth factor β receptor type II gene mutation common in colon and gastric but rare in endometrial cancers with microsatellite instability. Cancer Res. 1995, 55: 5545-5547.PubMed
15.
Parsons R, Myeroff LL, Liu B, et al: Microsatellite instability and mutations of the transforming growth factor β type II receptor gene in colorectal cancer. Cancer Res. 1995, 55: 5548-5550.PubMed
16.
Grady WM, Myeroff LL, Swinler SE, et al: Mutational inactivation of transforming growth factor β receptor type II in microsatellite stable colon cancers. Cancer Res. 1999, 59: 320-324.PubMed
17.
D'Abronzo FH, Swearingen B, Klibanski A, Alexander JM: Mutational analysis of activin/transforming growth factor-β type I and type II receptor kinases in human pituitary tumors. J Clin Endocrinol Metab. 1999, 84: 1716-1721. 10.1210/jc.84.5.1716.PubMedCrossRef
18.
Kaneko H, Horiike S, Taniwaki M, Misawa S: Microsatellite instability is an early genetic event in myelodysplastic syndrome but is infrequent and not associated with TGF-β receptor type II gene mutation. Leukemia. 1996, 10: 1696-1699.PubMed
19.
Venkatasubbarao K, Ahmed MM, Swiderski C, et al: Novel mutations in the polyadenine tract of the transforming growth factor β type II receptor gene are found in a subpopulation of human pancreatic adenocarcinomas. Genes Chromosomes Cancer. 1998, 22: 138-144. 10.1002/(SICI)1098-2264(199806)22:2<138::AID-GCC8>3.0.CO;2-Y.PubMedCrossRef
20.
Vincent F, Hagiwara K, Ke Y, Stoner GD, Demetrick DJ, Bennett WP: Mutation analysis of the transforming growth factor β type II receptor in sporadic human cancers of the pancreas, liver, and breast. Biochem Biophys Res Commun. 1996, 223: 561-564. 10.1006/bbrc.1996.0934.PubMedCrossRef
21.
Chen T, Carter D, Garrigue-Antar L, Reiss M: Transforming growth factor β type I receptor kinase mutant associated with metastatic breast cancer. Cancer Res. 1998, 58: 4805-4810. This is the first report of mutations in TβR-I in human cancer. The predominance of the mutation in lymph node metastases suggests an importance for breast cancer progression.PubMed
22.
Takenoshita S, Mogi A, Tani M, et al: Absence of mutations in the analysis of coding sequences of the entire transforming growth factor-β type II receptor gene in sporadic human breast cancers. Oncol Rep. 1998, 5: 367-371.PubMed
23.
Tomita S, Deguchi S, Miyaguni T, Muto Y, Tamamoto T, Toda T: Analyses of microsatellite instability and the transforming growth factor-β receptor type II gene mutation in sporadic breast cancer and their correlation with clinicopathological features. Breast Cancer Res Treat. 1999, 53: 33-39. 10.1023/A:1006167210269.PubMedCrossRef
24.
Vincent F, Nagashima M, Takenoshita S, et al: Mutation analysis of the transforming growth factor-β type II receptor in human cell lines resistant to growth inhibition by transforming growth factor-β. Oncogene. 1997, 15: 117-122. 10.1038/sj.onc.1201166.PubMedCrossRef
25.
Markowitz SD, Roberts AB: Tumor suppressor activity of the TGF-β pathway in human cancers. Cytokine Growth Factor Rev. 1996, 7: 93-102. 10.1016/1359-6101(96)00001-9.PubMedCrossRef
26.
Goggins M, Shekher M, Turnacioglu K, Yeo CJ, Hruban RH, Kern SE: Genetic alterations of the transforming growth factor β receptor genes in pancreatic and biliary adenocarcinomas. Cancer Res. 1998, 58: 5329-5332.PubMed
27.
Schiemann WP, Pfeifer WM, Levi E, Kadin ME, Lodish HF: A deletion in the gene for transforming growth factor β type I receptor abolishes growth regulation by transforming growth factor β in a cutaneous T-cell lymphoma. Blood. 1999, 94: 2854-2861.PubMed
28.
Chen T, de Vries EG, Hollema H, et al: Structural alterations of transforming growth factor-β receptor genes in human cervical carcinoma. Int J Cancer. 1999, 82: 43-51. 10.1002/(SICI)1097-0215(19990702)82:1<43::AID-IJC9>3.0.CO;2-0.PubMedCrossRef
29.
Pasche B, Kolachana P, Nafa K, et al: TβR-I(6A) is a candidate tumor susceptibility allele. Cancer Res. 1999, 59: 5678-5682.PubMed
30.
Anbazhagan R, Bornman DM, Johnston JC, Westra WH, Gabrielson E: The S387Y mutations of the transforming growth factor-β receptor type I gene is uncommon in metastases of breast cancer and other common types of adenocarcinoma. Cancer Res. 1999, 59: 3363-3364. This study failed to identify the mutation reported in [21•] in breast cancer metastases and other forms of adenocarcinomas. The importance of such a mutation for breast or other cancers is therefore questioned.PubMed
31.
Hahn SA, Schutte M, Hoque ATMS, et al: DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science. 1996, 271: 350-353. This study identifies Smad4/DPC4 as a candidate tumor suppressor that is inactivated in a large percentage of pancreatic carcinomas, and possibly also in other human cancers.PubMedCrossRef
32.
Barrett MT, Schutte M, Kern SE, Reid BJ: Allelic loss and mutational analysis of the DPC4 gene in esophageal adenocarcinoma. Cancer Res. 1996, 56: 4351-4353.PubMed
33.
Kim SK, Fan Y, Papadimitrakopoulou V, et al: DPC4, a candidate tumor suppressor gene, is altered infrequently in head and neck squamous cell carcinoma. Cancer Res. 1996, 56: 2519-2521.PubMed
34.
Kawate S, Takenoshita S, Ohwada S, et al: Mutation analysis of transforming growth factor β type II receptor, Smad2, and Smad4 in hepatocellular carcinoma. Int J Oncol. 1999, 14: 127-131.PubMed
35.
Kong XT, Choi SH, Inoue A, et al: Expression and mutational analysis of the DCC, DPC4, and MADR2/JV18-1 genes in neuroblastoma. Cancer Res. 1997, 57: 3772-3778.PubMed
36.
Nagatake M, Takagi Y, Osada H, et al: Somatic in vivo alterations of the DPC4 gene at 18q21 in human lung cancers. Cancer Res. 1996, 56: 2718-2720.PubMed
37.
Schutte M, Hruban RH, Hedrik L, et al: DPC4 gene in various tumor types. Cancer Res. 1996, 56: 2527-2530.PubMed
38.
Eppert K, Scherer SW, Ozcelik H, et al: MADR2 maps to 18q21 and encodes a TGFβ-regulated MAD-related protein that is functionally mutated in colorectal carcinoma. Cell. 1996, 86: 543-552. 10.1016/S0092-8674(00)80128-2. This study identifies Smad2 as a candidate tumor suppressor that is inactivated in some colorectal carcinomas and is regulated specifically by TGF-β signaling. Its inactivation is likely to contribute to loss of TGF-β-mediated growth inhibition in affected cells.PubMedCrossRef
39.
Miyaki M, Iijima T, Konishi M, et al: Higher frequency of Smad4 gene mutation in human colorectal cancer with distant metastasis. Oncogene. 1999, 18: 3098-3103. 10.1038/sj.onc.1202642.PubMedCrossRef
40.
Riggins GJ, Thiagalingam S, Rozenblum E, et al: Mad-related genes in the human. Nat Genet. 1996, 13: 347-349.PubMedCrossRef
41.
42.
Uchida K, Nagatake M, Osada H, et al: Somatic in vivo alterations of the JV18-1 gene at 18q21 in human lung cancers. Cancer Res. 1996, 56: 5583-5585.PubMed
43.
Bevan S, Woodford-Richens K, Rozen P, et al: Screening SMAD1, SMAD2, SMAD3, and SMAD5 for germline mutations in juvenile polyposis syndrome. Gut. 1999, 45: 406-408.PubMedPubMedCentralCrossRef
44.
Jonson T, Gorunova L, Dawiskiba S, et al: Molecular analyses of the 15q and 18q SMAD genes in pancreatic cancer. Genes Chromosomes Cancer. 1999, 24: 62-71. 10.1002/(SICI)1098-2264(199901)24:1<62::AID-GCC9>3.0.CO;2-4.PubMedCrossRef
45.
Ikezoe T, Takeuchi S, Kamioka M, et al: Analysis of the Smad2 gene in hematological malignancies. Leukemia. 1998, 12: 94-95. 10.1038/sj.leu.2400888.PubMedCrossRef
46.
Latil A, Pesche S, Valeri A, Fournier G, Cussenot O, Lidereau R: Expression and mutational analysis of the MADR2/Smad2 gene in human prostate cancer. Prostate. 1999, 40: 225-231. 10.1002/(SICI)1097-0045(19990901)40:4<225::AID-PROS3>3.0.CO;2-3.PubMedCrossRef
47.
Maesawa C, Tamura G, Nishizuka S, et al: MAD-related genes on 18q21.1, Smad2 and Smad4, are altered infrequently in esophageal squamous cell carcinoma. Jpn J Cancer Res. 1997, 88: 340-343.PubMedCrossRef
48.
Roth S, Sistonen P, Salovaara R, et al: SMAD genes in juvenile polyposis. Genes Chromosomes Cancer. 1999, 26: 54-61. 10.1002/(SICI)1098-2264(199909)26:1<54::AID-GCC8>3.0.CO;2-D.PubMedCrossRef
49.
Shitara Y, Yokozaki H, Yasui W, et al: No mutations of the Smad2 gene in human sporadic gastric carcinomas. Jpn J Clin Oncol. 1999, 29: 3-7. 10.1093/jjco/29.1.3.PubMedCrossRef
50.
Wieser R, Gruber B, Rieder H, Fonatsch C: Mutational analysis of the tumor suppressor Smad2 in acute lymphoid and myeloid leukemia. Leukemia. 1998, 12: 1114-1118. 10.1038/sj.leu.2401073.PubMedCrossRef
51.
Yokota T, Matsumoto S, Yoshimoto M, et al: Mapping of a breast cancer tumor suppressor gene locus to a 4-cM interval on chromosome 18q21. Jpn J Cancer Res. 1997, 88: 959-964.PubMedCrossRef
52.
Arai T, Akiyama Y, Okabe S, Ando M, Endo M, Yuasa Y: Genomic structure of the human Smad3 gene and its infrequent alterations in colorectal cancers. Cancer Lett. 1998, 122: 157-163. 10.1016/S0304-3835(97)00384-4.PubMedCrossRef
53.
Riggins GJ, Kinzler KW, Vogelstein B, Thiagalingam S: Frequency of Smad mutations in human cancers. Cancer Res. 1997, 57: 2578-2580.PubMed
54.
Wang D, Kanuma T, Takama F, et al: Mutation analysis of the smad3 gene in human ovarian cancers. Int J Oncol. 1999, 15: 949-953. 10.1021/bp990088o.PubMed
55.
Kalkhoven E, Roelen BA, de Winter JP, et al: Resistance to transforming growth factor β and activin due to reduced receptor expression in human breast tumor cell lines. Cell Growth Diff. 1995, 6: 1151-1161. This study demonstrates that in some breast cancer cells, loss of TGF-β growth inhibition is due to reduced expression of TβR-II. Exogenous expression of TβR-II can restore TGF-β sensitivity.PubMed
56.
Ko Y, Banerji SS, Liu Y, et al: Expression of transforming growth factor-β receptor type II and tumorigenicity in human breast adenocarcinoma MCF-7 cells. J Cell Physiol. 1998, 176: 424-434. 10.1002/(SICI)1097-4652(199808)176:2<424::AID-JCP21>3.0.CO;2-1.PubMedCrossRef
57.
Sun L, Wu G, Willson JK, et al: Expression of transforming growth factor β type II receptor leads to reduced malignancy in human breast cancer MCF-7 cells. J Biol Chem. 1994, 269: 26449-26455. This study demonstrates that in a breast cancer cell line, loss of TGFβ growth inhibition is due to reduced expression of TβR-II. Exogenous expression of TβR-II can restore TGFβ sensitivity and reduce malignancy of the cells.PubMed
58.
Chakravarthy D, Green AR, Green VL, Kerin MJ, Speirs V: Expression and secretion of TGF-β isoforms and expression of TGF-β-receptors I,II and III in normal and neoplastic human breast. Int J Oncol. 1999, 15: 187-194.PubMed
59.
Baldwin RL, Friess H, Yokoyama M, et al: Attenuated ALK5 receptor expression in human pancreatic cancer: correlation with resistance to growth inhibition. Int J Cancer. 1996, 67: 283-288. 10.1002/(SICI)1097-0215(19960717)67:2<283::AID-IJC21>3.0.CO;2-B.PubMedCrossRef
60.
Wagner M, Kleeff J, Lopez ME, Bockman I, Massaque J, Korc M: Transfection of the type I TGF-β receptor restores TGF-β responsiveness in pancreatic cancer. Int J Cancer. 1998, 78: 255-260. 10.1002/(SICI)1097-0215(19981005)78:2<255::AID-IJC21>3.0.CO;2-8.PubMedCrossRef
61.
Wang J, Han W, Zborowska E, et al: Reduced expression of transforming growth factor β type I receptor contributes to the malignancy of human colon carcinoma cells. J Biol Chem. 1996, 271: 17366-17371. 10.1074/jbc.271.29.17366.PubMedCrossRef
62.
DeCoteau JF, Knaus PI, Yankelev H, et al: Loss of functional cell surface transforming growth factor β (TGF-β) type 1 receptor correlates with insensitivity to TGF-β in chronic lymphocytic leukemia. Proc Natl Acad Sci USA. 1997, 94: 5877-5881. 10.1073/pnas.94.11.5877.PubMedPubMedCentralCrossRef
63.
Pouliot F, Labrie C: Expression profile of agonistic Smads in human breast cancer cells: absence of regulation by estrogens. Int J Cancer. 1999, 81: 98-103. 10.1002/(SICI)1097-0215(19990331)81:1<98::AID-IJC17>3.0.CO;2-9.PubMedCrossRef
64.
Kretzschmar M, Doody J, Timokhina I, Massagué J: A mechanism of repression of TGFβ/Smad signaling by oncogenic Ras. Genes Dev. 1999, 13: 804-816. This study describes a novel mechanism of regulation of TGF-β/SMAD signaling via phosphorylation of SMAD proteins by Erk MAP-kinase. This mechanism contributes to loss of TGF-β growth inhibition in Ras-transformed epithelial cells, and may be of importance in cancer cells with elevated Ras and Erk activities.PubMedPubMedCentralCrossRef
65.
Calonge MJ, Massague J: Smad4/DPC4 silencing and hyperactive ras jointly disrupt transforming growth factor-β antiproliferative responses in colon cancer cells. J Biol Chem. 1999, 274: 33637-33643. 10.1074/jbc.274.47.33637.PubMedCrossRef
66.
Marshall C: How do small GTPase signal transduction pathways regulate cell cycle entry?. Curr Opin Cell Biol. 1999, 11: 732-736. 10.1016/S0955-0674(99)00044-7.PubMedCrossRef
67.
Rochlitz CF, Scott GK, Dodson JM, et al: Incidence of activating ras oncogene mutations associated with primary and metastatic human breast cancer. Cancer Res. 1989, 49: 357-360.PubMed
68.
Dillon DA, Howe CL, Bosari S, Costa J: The molecular biology of breast cancer: accelerating clinical applications. Crit Rev Oncog. 1998, 9: 125-140.PubMedCrossRef
69.
Press MF, Bernstein L, Thomas PA, et al: HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol. 1997, 15: 2894-2904.PubMed
70.
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987, 235: 177-182.PubMedCrossRef
71.
Rajkumar T, Gullick WJ: The type I growth factor receptors in human breast cancer. Breast Cancer Res Treat. 1994, 29: 3-9.PubMedCrossRef
72.
Seshadri R, Firgaira FA, Horsfall DJ, McCaul K, Setlur V, Kitchen P: Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. J Clin Oncol. 1993, 11: 1936-1942.PubMed
73.
de Caestecker MP, Parks WT, Frank CJ, et al: Smad2 transduces common signals from receptor serine-threonine and tyrosine kinases. Genes Dev. 1998, 12: 1587-1592.PubMedPubMedCentralCrossRef
74.
Piek E, Heldin CH, Ten Dijke P: Specificity, diversity, and regulation in TGF-β superfamily signaling. FASEB J. 1999, 13: 2105-2124.PubMed
75.
76.
Hayashi H, Abdollah S, Qiu Y, et al: The MAD-related protein Smad7 associates with the TGFβ receptor and functions as an antagonist of TGFβ signaling. Cell. 1997, 89: 1165-1173. 10.1016/S0092-8674(00)80303-7. This study identifies a novel mechanism of regulation of TGF-β family signaling that involves a new class of SMAD proteins, the inhibitory SMAD proteins. Inhibition is mediated by competition between the inhibitory SMAD and receptor-regulated SMAD proteins for interaction with the receptors.PubMedCrossRef
77.
Imamura T, Takase M, Nishihara A, et al: Smad6 inhibits signalling by the TGF-β superfamily. Nature. 1997, 389: 622-626. 10.1038/39355.PubMedCrossRef
78.
Nakao A, Afrakhte M, Morén A, et al: Identification of Smad7, a TGFβ-inducible antagonist of TGF-β signaling. Nature. 1997, 389: 631-635. 10.1038/39369.PubMedCrossRef
79.
Hata A, Lagna G, Massagué J, Hemmati-Brivanlou A: Smad6 inhibits BMP/Smad1 signaling by specifically competing with the Smad4 tumor suppressor. Genes Dev. 1998, 12: 186-197. This study identifies a novel mechanism of regulation of TGF-β family signaling that involves a new class of SMAD proteins, the inhibitory SMAD proteins. Inhibition is mediated by competition between the inhibitory SMAD and Smad4 for association with receptor-activated SMAD proteins.PubMedPubMedCentralCrossRef
80.
Afrakhte M, Moren A, Jossan S, et al: Induction of inhibitory Smad6 and Smad7 mRNA by TGF-β family members. Biochem Biophys Res Commun. 1998, 249: 505-511. 10.1006/bbrc.1998.9170.PubMedCrossRef
81.
Takase M, Imamura T, Sampath TK, et al: Induction of Smad6 mRNA by bone morphogenetic proteins. Biochem Biophys Res Commun. 1998, 244: 26-29. 10.1006/bbrc.1998.8200.PubMedCrossRef
82.
Kleeff J, Maruyama H, Friess H, Buchler MW, Falb D, Korc M: Smad6 suppresses TGF-β-induced growth inhibition in COLO-357 pancreatic cancer cells and is overexpressed in pancreatic cancer. Biochem Biophys Res Commun. 1999, 255: 268-273. 10.1006/bbrc.1999.0171.PubMedCrossRef
83.
Kleeff J, Ishiwata T, Maruyama H, et al: The TGF-β signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer. Oncogene. 1999, 18: 5363-5372. 10.1038/sj.onc.1202909. This study provides evidence that elevated expression of inhibitory SMAD proteins may play a role in human cancer.PubMedCrossRef
84.
Korchynskyi O, Landstrom M, Stoika R, et al: Expression of Smad proteins in human colorectal cancer. Int J Cancer. 1999, 82: 197-202. 10.1002/(SICI)1097-0215(19990719)82:2<197::AID-IJC8>3.0.CO;2-V.PubMedCrossRef
85.
Akiyoshi S, Inoue H, Hanai J-i, et al: c-Ski acts as a transcriptional Co-repressor in transforming growth factor-β signaling through interaction with Smads. J Biol Chem. 1999, 274: 35269-35277. 10.1074/jbc.274.49.35269. This study identifies the oncoprotein c-Ski as a transcriptional corepressor for SMAD proteins that can inhibit TGF-β signaling when overexpressed. This suggests that inhibition of TGF-β signaling might be an important component of the oncogenic properties of c-Ski.PubMedCrossRef
86.
Luo K, Stroschein SL, Wang W, et al: The Ski oncoprotein interacts with the Smad proteins to repress TGFβ signaling. Genes Dev. 1999, 13: 2196-2206. 10.1101/gad.13.17.2196.PubMedPubMedCentralCrossRef
87.
Stroschein SL, Wang W, Zhou S, Zhou Q, Luo K: Negative feedback regulation of TGF-β signaling by the SnoN oncoprotein. Science. 1999, 286: 771-774. 10.1126/science.286.5440.771. This study identifies the oncoprotein c-SnoN as a transcriptional corepressor for SMAD proteins that maintains TGF-β-responsive genes in a repressed state in the absence of TGF-β signaling and is involved in negative feedback regulation subsequent to TGF-β stimulation.PubMedCrossRef
88.
Sun Y, Liu X, Ng-Eaton E, Lodish HF, Weinberg RA: SnoN and ski protooncoproteins are rapidly degraded in response to transforming growth factor β signaling. Proc Natl Acad Sci USA. 1999, 96: 12442-12447. 10.1073/pnas.96.22.12442.PubMedPubMedCentralCrossRef
89.
Sun Y, Liu X, Eaton EN, Lane WS, Lodish HF, Weinberg RA: Interaction of the Ski oncoprotein with Smad3 regulates TGF-β signaling. Mol Cell. 1999, 4: 499-509.PubMedCrossRef
90.
Wotton D, Lo RS, Lee S, Massague J: A Smad transcriptional corepressor. Cell. 1999, 97: 29-39. This study describes a novel mechanism of regulation of nuclear SMAD activity that involves the interaction of SMAD proteins with a transcriptional corepressor, TGIF. TGIF competes with association of SMAD proteins with the coactivators p300/CBP, presumably resulting in opposing effects on histone acetylation.PubMedCrossRef
91.
Nomura T, Khan MM, Kaul SC, et al: Ski is a component of the histone deacetylase complex required for transcriptional repression by Mad and thyroid hormone receptor. Genes Dev. 1999, 13: 412-423.PubMedPubMedCentralCrossRef
92.
Kouzarides T: Histone acetylases and deacetylases in cell proliferation. Curr Opin Genet Dev. 1999, 9: 40-48. 10.1016/S0959-437X(99)80006-9.PubMedCrossRef
93.
Colmenares C, Sutrave P, Hughes SH, Stavnezer E: Activation of the c-ski oncogene by overexpression. J Virol. 1991, 65: 4929-4935.PubMedPubMedCentral
94.
Fumagalli S, Doneda L, Nomura N, Larizza L: Expression of the c-ski proto-oncogene in human melanoma cell lines. Melanoma Res. 1993, 3: 23-27.PubMedCrossRef
95.
Nomura N, Sasamoto S, Ishii S, Date T, Matsui M, Ishizaki R: Isolation of human cDNA clones of ski and the ski-related gene, sno. Nucleic Acids Res. 1989, 17: 5489-5500.PubMedPubMedCentralCrossRef
96.
Yamanouchi K, Soeta C, Harada R, Naito K, Tojo H: Endometrial expression of cellular protooncogene c-ski and its regulation by estradiol-17β. FEBS Lett. 1999, 449: 273-276. 10.1016/S0014-5793(99)00424-X.PubMedCrossRef
97.
Nucifora G: The EVI1 gene in myeloid leukemia. Leukemia. 1997, 11: 2022-2031. 10.1038/sj.leu.2400880.PubMedCrossRef
98.
Kurokawa M, Mitani K, Irie K, et al: The oncoprotein Evi-1 represses TGF-β signalling by inhibiting Smad3. Nature. 1998, 394: 92-96. 10.1038/27945. This study identifies the oncoprotein Evi-1 as a repressor of growth inhibitory TGF-β signaling. Repression is achieved by direct interaction between Evi-1 and Smad3, resulting in the inhibition of Smad3 transcriptional activity.PubMedCrossRef
99.
Kurokawa M, Mitani K, Imai Y, Ogawa S, Yazaki Y, Hirai H: The t(3;21) fusion product, AML1/Evi-1, interacts with Smad3 and blocks transforming growth factor-β-mediated growth inhibition of myeloid cells. Blood. 1998, 92: 4003-4012.PubMed
100.
101.
Kurokawa M, Ogawa S, Tanaka T, et al: The AML1/Evi-1 fusion protein in the t(3;21) translocation exhibits transforming activity on Rat1 fibroblasts with dependence on the Evi-1 sequence. Oncogene. 1995, 11: 833-840.PubMed
102.
Kilbey A, Stephens V, Bartholomew C: Loss of cell cycle control by deregulation of cyclin-dependent kinase 2 kinase activity in Evi-1 transformed fibroblasts. Cell Growth Diff. 1999, 10: 601-610.PubMed
103.
Onichtchouk D, Chen YG, Dosch R, et al: Silencing of TGF-β signalling by the pseudoreceptor BAMBI. Nature. 1999, 401: 480-485. 10.1038/46794. This study describes a novel transmembrane protein, BAMBI, that is similar to type I TGF-β receptors but lacks a kinase domain. BAMBI can inhibit TGF-β family signaling by preventing the formation of signaling competent receptor complexes.PubMedCrossRef
104.
Degen WG, Weterman MA, van Groningen JJ, et al: Expression of nma, a novel gene, inversely correlates with the metastatic potential of human melanoma cell lines and xenografts. Int J Cancer. 1996, 65: 460-465. 10.1002/(SICI)1097-0215(19960208)65:4<460::AID-IJC12>3.0.CO;2-E.PubMedCrossRef
105.
Donovan J, Slingerland J: Transforming growth factor-β and breast cancer: cell cycle arrest by transforming growth factor-β and its disruption in cancer. Breast Cancer Res. 2000, 2: 116-124. 10.1186/bcr43.PubMedPubMedCentralCrossRef
Metadata
Title
Transforming growth factor-β and breast cancer: Transforming growth factor-β/SMAD signaling defects and cancer
Author
Marcus Kretzschmar
Publication date
01-04-2000
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 2/2000
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr42

Other articles of this Issue 2/2000

Breast Cancer Research 2/2000 Go to the issue

Review

Transforming growth factor-β and breast cancer: Lessons learned from genetically altered mouse models

Meeting report

22nd Annual San Antonio Breast Cancer Symposium, 8-11 December 1999, San Antonio, Texas, USA

Review

Signal transducers and activators of transcription as regulators of growth, apoptosis and breast development

Commentary

Breast cancer research: where we are and where we should go

Commentary

Caretaker Brca1: keeping the genome in the straight and narrow

Review

Transforming growth factor-β and breast cancer: Cell cycle arrest by transforming growth factor-β and its disruption in cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits